ReviewiScience2026
Crosstalk between ubiquitination and other post-translational modifications in cardiovascular diseases.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain a major cause of morbidity and mortality worldwide. Post-translational modifications (PTMs) are increasingly recognized as important regulators of cardiovascular pathophysiology, but how different PTMs interact in CVDs is still incompletely understood. This review focuses on the crosstalk between ubiquitination and other PTMs, including phosphorylation, SUMOylation, acetylation, methylation, O-GlcNAcylation, neddylation, and ADP-ribosylation/PARylation. We summarize representative cardiovascular mechanisms in which these modifications act competitively, cooperatively, or sequentially to influence protein stability, signaling, and function. We also discuss current limitations in establishing PTM interactions and highlight areas that require further investigation. A clearer understanding of these regulatory relationships may help identify disease-relevant PTM pathways and potential therapeutic targets in CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.